AVBP supply chain intelligence for ArriVent BioPharma, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
ArriVent BioPharma, Inc. (AVBP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SYNTHEALL-PHARMACEUTICAL-CO-LTD | SYNTHEALL-PHARMACEUTICAL-CO-LTD | 92% | Currently, we rely on, and have agreements with, two third-party contract manufacturers, Zhejiang Raybow Pharmaceutical Company., Ltd. (Raybow) and SynTheAll Pharmaceutical Co., Ltd. (WuXi STA) to su… |
| WUXI-STA | WUXI-STA | 92% | Currently, we rely on, and have agreements with, two third-party contract manufacturers, Zhejiang Raybow Pharmaceutical Company., Ltd. (Raybow) and SynTheAll Pharmaceutical Co., Ltd. (WuXi STA) to su… |
| ZHEJIANG-RAYBOW-PHARMACEUTICAL-COMPANY-LTD | ZHEJIANG-RAYBOW-PHARMACEUTICAL-COMPANY-LTD | 92% | Currently, we rely on, and have agreements with, two third-party contract manufacturers, Zhejiang Raybow Pharmaceutical Company., Ltd. (Raybow) and SynTheAll Pharmaceutical Co., Ltd. (WuXi STA) to su… |
| CONTRACT-RESEARCH-ORGANIZATIONS-CROS | CONTRACT-RESEARCH-ORGANIZATIONS-CROS | 90% | external research and development costs incurred under agreements with contract research organizations (CROs) and consultants to conduct our clinical trials |
| RAW-MATERIAL-SUPPLIERS | RAW-MATERIAL-SUPPLIERS | 90% | costs related to manufacturing our product candidates, including fees paid to third-party manufacturers and raw material suppliers |
| WUXI-XDC-CAYMAN-INC | WUXI-XDC-CAYMAN-INC | 90% | We expect to rely on manufacturers in China for ARR-217 drug substance and drug product for use in initial clinical studies and also expect to rely on WuXi XDC Cayman, Inc., (WuXi XDC) for the manufa… |
| AARVIK | AARVIK | 80% | We also have commitments for obligations under our agreements with Allist, Alphamab, Aarvik, and Lepu. |
| ALLIST | ALLIST | 80% | We also have commitments for obligations under our agreements with Allist, Alphamab, Aarvik, and Lepu. |
| ALPHAMAB | ALPHAMAB | 80% | We also have commitments for obligations under our agreements with Allist, Alphamab, Aarvik, and Lepu. |
| LEPU | LEPU | 80% | We also have commitments for obligations under our agreements with Allist, Alphamab, Aarvik, and Lepu. |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| DIZAL-PHARMACEUTICAL | DIZAL-PHARMACEUTICAL | 90% | In July 2025, Dizal Pharmaceutical announced the FDA approval of sunvozertinib in second or later line NSCLC patients with EGFR exon 20 insertion mutations. |
| BDTX | Black Diamond Therapeutics, Inc. | 72% | Reciprocal relationship from BDTX graph: Reciprocal relationship from AVBP graph: Reciprocal relationship from BDTX graph: Reciprocal relationship from AVBP graph: Reciprocal relationship from BDTX g… |
| BDTX | Black Diamond Therapeutics, Inc. | 72% | therwise prefer to develop and market ourselves. We also face substantial competition from multiple sources, including large and specialty pharmaceutical and biotechnology companies, academic researc… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | Reciprocal relationship from CGEM graph: Reciprocal relationship from AVBP graph: therwise prefer to develop and market ourselves. We also face substantial competition from multiple sources, includin… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | therwise prefer to develop and market ourselves. We also face substantial competition from multiple sources, including large and specialty pharmaceutical and biotechnology companies, academic researc… |
| JNJ | Johnson & Johnson | 72% | therwise prefer to develop and market ourselves. We also face substantial competition from multiple sources, including large and specialty pharmaceutical and biotechnology companies, academic researc… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from AVBP graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AVBP graph: therwise prefer to develop and market… |
| BAYER-AG | BAYER-AG | 62% | therwise prefer to develop and market ourselves. We also face substantial competition from multiple sources, including large and specialty pharmaceutical and biotechnology companies, academic researc… |
| CULLINAN-THERAPEUTICS-INC-TAIHO-PHARMACEUTICAL-C | CULLINAN-THERAPEUTICS-INC-TAIHO-PHARMACEUTICAL-C | 62% | therwise prefer to develop and market ourselves. We also face substantial competition from multiple sources, including large and specialty pharmaceutical and biotechnology companies, academic researc… |
| THERAPEUTICS-DIZAL-PHARMACEUTICAL-ORIC-PHARMACEU | THERAPEUTICS-DIZAL-PHARMACEUTICAL-ORIC-PHARMACEU | 62% | therwise prefer to develop and market ourselves. We also face substantial competition from multiple sources, including large and specialty pharmaceutical and biotechnology companies, academic researc… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| AVBP-DEBT | Debt stack $419,000 | 90% | Market cache reports total debt of $419,000. |
| AVBP-DEBT-14222 | Warrants outstanding: 0.0001 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| AVBP-DEBT-7992 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| AVBP-OWNER-SUVRETTA-CAPITAL-MANAGEMENT-LLC | SUVRETTA CAPITAL MANAGEMENT, LLC | 90% | 13F overlay lists SUVRETTA CAPITAL MANAGEMENT, LLC as top holder; 140 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ACIU | AC Immune SA | 100.00 | 2 | |
| FDMT | 4D Molecular Therapeutics, Inc. | 100.00 | 2 | |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 | |
| ABBV | AbbVie Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| ATON | AlphaTON Capital Corp | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| CLGN | CollPlant Biotechnologies Ltd. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ADGM | Adagio Medical Holdings, Inc. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| AURA | Aura Biosciences, Inc. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| SNNUF | Smith & Nephew plc | 100.00 | 2 | |
| ALC | Alcon Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| CRIS | Curis, Inc. | 100.00 | 2 |